Deal Watch: Merck Hopes Moderna's Personalized Vaccines Can Increase Keytruda Patient Base
Novartis and Xencor sign wide-ranging immuno-oncology collaboration targeting multiple CD pathways. Teva signs divestment agreements with five firms during June to meet FTC requirements for its acquisition of Allergan's generics business.
You may also be interested in...
Verastem steps in where AbbVie exited, agreeing to license Infinity’s duvelisib in hematologic cancer indications. Celldex grows its immuno-oncology pipeline with buyout of private Yale Medical School-spinout Kolltan.
One case of adjudicated arthropathy seen in halted Phase IIb study of anti-NGF candidate. Regeneron still hopes to advance fasinumab, partnered with Teva, into Phase III in osteoarthritis and chronic low back pain – but the second clinical hold for the class puts its future into even greater question.
A pending agreement includes a $5.2bn cash payment from Boehringer to Sanofi but excludes Boehringer’s consumer product business in China. The brands Sanofi will add to its consumer health lineup include two marketed in the US, Dulcolax constipation relief and Zantac heartburn remedy.